A Study in People With Mild Hypertension

Lilly

Status and phase: Completed; Phase 2

Conditions: Mild Hypertension

Treatments: Drug: Hydrochlorothiazide; Drug: Placebo; Drug: PPAR alpha

Study type: Interventional

Funder types: Industry

Identifiers

NCT00374855

9593

H8D-MC-EMBH

Details and patient eligibility

About

The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Are men and women between 18 and 70 years of age, inclusive
2. Have given signed informed consent to participate in this study
3. Are diagnosed with mild essential hypertension at screening (currently untreated or treated with monotherapy)

Exclusion criteria

1. Secondary or malignant hypertension
2. Have or have had a history of hyperlipidemia within 3 months of screening requiring treatment
3. Any previous cardiovascular disease other than hypertension
4. Type 1 or 2 diabetes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind